BG-12, an immunomodulatory dimethylfumarate

Current Opinion in Investigational Drugs

Volumn 8, Issue 11, 2007, Pages 955-962

  Wakkee, M ^a   Thio, H B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BG 00012; CORTICOSTEROID; DIMETHYLFUMARATE; FAG 201; FUMADERM; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; LIVER ENZYME; METHOTREXATE; METHYLHYDROGENFUMARATE; MONOETHYLFUMARATE; MONOMETHYLFUMARATE; PLACEBO; UNCLASSIFIED DRUG; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ALLERGIC ENCEPHALOMYELITIS; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; COMMON COLD; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; DRUG WITHDRAWAL; FLUSHING; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; IMMUNOMODULATION; LIVER FUNCTION TEST; MULTIPLE SCLEROSIS; NAUSEA; NEPHROLITHIASIS; NONHUMAN; PATENT; PNEUMONIA; PRURITUS; PSORIASIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; UNITED STATES; ANIMAL; CHEMISTRY; PHASE 3 CLINICAL TRIAL;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 35948981177     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 507235 Biogen licenses psoriasis drug from Fumapharm. Biogen Inc PRESS RELEASE 2003 October 01
2. 594111 Biogen and Fumapharm's BG-12 meets phase III psoriasis endpoint. Biogen Idec Inc PRESS RELEASE 2005 April 07
3. 670177 Oral compound BG-12 achieves primary endpoint in phase II study of relapsing-remitting multiple sclerosis; treatment with BG-12 led to statistically significant reductions in MRI measures. Biogen Idec Inc PRESS RELEASE 2006 May 30
4. 670404 Biogen Idec to buy Fumapharm. Biogen Idec Inc PRESS RELEASE 2006 May 31
5. 756337 Biogen Idec's BG-12 enters phase III MS trials. Biogen Idec Inc PRESS RELEASE 2007 January 09
6. 760106 Treatment of moderate-to-severe psoriasis with oral dimethyl fumarate (BG00012): Results of a multicentre, randomized, double-blind, placebo-controlled trial. Mrowietz U, Reich K, Spellman MC BR J DERMATOL 2006 154 1 Abs
7. 760107 Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pohlau D, Przuntek H EUR J NEUROL 2006 13 6 604-610
8. 760108 Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Schilling S, Goelz S, Linker R, Luehder F, Gold R CLIN EXP IMMUNOL 2006 145 1 101-107
9. 760110 Dimethyl fumarate (BG00012) as an oral therapy for moderate to severe psoriasis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Mrowietz U, Spellman M J INVEST DERMATOL 2005 125 3 Suppl A69
10. 787703 Biogen Idec pipeline. Biogen Idec Inc COMPANY WORLD WIDE WEB SITE 2007 April 26
11. 824877 Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, van Dijk E J AM ACAD DERMATOL 1989 20 4 601-608
12. 824878 Treatment of psoriasis vulgaris. Schweckendiek W MED MONATSSCHR PHARM 1959 13 2 103-104
13. 824891 Dimethylfumarate for psoriasis: More than a dietary curiosity. Mrowietz U, Asadullah K TRENDS MOL MED 2005 11 1 43-48
14. 824892 In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. Litjens NH, van Strijen E, van Gulpen C, Mattie H, van Dissel JT, Thio HB, Nibbering PH BMC PHARMACOL 2004 4 22
15. 824898 An approach to the treatment of moderate to severe psoriasis with rotational therapy. Weinstein GD, White GM J AM ACAD DERMATOL 1993 28 3 454-459
16. 824899 Use of fumaric acid esters in psoriasis. Roll A, Reich K, Boer A INDIAN J DERMATOL VENEREOL LEPROL 2007 73 2 133-137
17. 824901 Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: Results of a phase 2 study. Kappos L, Miller DH, MacManus DG, Gold R, Havrdova E, Limmroth V, Polman C, Schmierer K, Yousry T, Yang M, Eraksoy M et al J NEUROL 2006 253 Suppl 2 27
18. 824905 Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D J AM ACAD DERMATOL 1999 22 2 Pt 1 311-312
19. 824907 Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes. Thio HB, Zomerdijk TP, Oudshoorn C, Kempenaar J, Nibbering PH, van der Schroeff JG, Ponec M BR J DERMATOL 1994 131 6 856-861
20. 824908 Inhibitory effects of fumaric acid derivates on cell proliferation and differentiation. Van der Schroeff JG, Oudshoorn C, Nugteren-Huying WM, Ponec M J INVEST DERMATOL 1989 92 537
21. 824909 The antipsoriatic agent dimethylfumarate immunomodulates Tcell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M BR J DERMATOL 1998 139 3 390-395
22. 824910 Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Vandermeeren M, Janssens S, Borgers M, Geysen J BIOCHEM BIOPHYS RES COMMUN 1997 234 1 19-23
23. 824912 Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, von Bonin A, Hennekes HH, Asadullah K, Docke WD J INVEST DERMATOL 2007 127 4 835-845
24. 824913 Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): Possible role for its anti-psoriatic effect. Gesser B, Johansen C, Rasmussen MK, Funding AT, Otkjaer K, Kjellerup RB, Kragballe K, Iversen L J INVEST DERMATOL 2007 127 9 2129-2137
25. 824914 Fumaric acid esters are potent immunosuppressants: Inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate Lehmann M, Risch K, Nizze H, Lutz J, Heemann U, Volk HD, Asadullah K ARCH DERMATOL RES 2002 294 9 399-404
26. 824915 Dimethylfumarate impairs melanoma growth and metastasis. Loewe R, Valero T, Kremling S, Pratscher B, Kunstfeld R, Pehamberger H, Petzelbauer P CANCER RES 2006 66 24 11888-11896
27. 824916 Results of a phase 2 dose-ranging and safety extension study of a novel oral fumarate, BG-12, in patients with severe psoriasis. Langncr A, Spellman MC J AM ACAD DERMATOL 2005 52 Suppl 193
28. 824917 Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study. German multicentre study. Mrowietz U, Christophers E, Altmeyer P BR J DERMATOL 1998 138 3 456-460
29. 824918 Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN BR J DERMATOL 2003 149 2 363-369
30. 830284 NCT00420212: Efficacy and safety of BG00012 in relapsing-remitting multiple sclerosis (DEFINE). Biogen Idec WWW.CLINICALTRIALS.GOV 2007 September 05
31. 830285 NCT00451451: Efficacy and safety study of BG00012 with active reference in relapsing-remitting multiple sclerosis (CONFIRM). Biogen Idec WWW.CLINICALTRIALS.GOV 2007 August 13
32. 833145 German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J et al ARCH DERMATOL RES 2007 299 3 111-138
33. 833210 Biological therapies in the systemic management of psoriasis: International Consensus Conference. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K et al BR J DERMATOL 2004 151 Suppl 69 3-17
34. 833214 High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. Lim JL, Stern RS J INVEST DERMATOL 2005 124 3 505-513
35. 833215 The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: A cohort study. Nijsten TE, Stern RS J INVEST DERMATOL 2003 121 2 252-258
36. 833217 Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J INVEST DERMATOL Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L 2003 120 2 211-216
37. 833219 Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters. Zhu K, Mrowietz U ARCH DERMATOL RES 2005 297 4 170-176
38. 833228 Evaluation of possible immune mediators causing flushing after BG00012 (dimethyl fumarate) administration in patients with psoriasis. Artuc M BR J DERMATOL SUPPL 2006 154 Suppl 1 11-35
39. 833244 Use of fumaric acid esters in psoriasis. Roll A, Reich K, Boer A INDIAN J DERMATOL VENEREOL LEPROL 2007 73 2 133-137
40. 833373 Psoriasis. Griffiths CEM, Camp RDR, Barker JNWN. In: ROOKS TEXTBOOK DERMATOL. 7th Edition. Burns DA, Breathnach SM, Cox NH, Griffiths CEM (Eds), Blackwell Publishing Ltd, Oxford, UK 2005 35 1-69
41. 834083 Psoriasis - recent advances in understanding its pathogenesis and treatment. Krueger G, Ellis CN J AM ACAD DERMATOL 2005 53 1 Suppl 1 94-100
42. 834090 Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis. Kappos L, Gold R, Miller D, MacManus D, Havrdova E, Limmroth V, Polman C, Schmierer K, Yousry T, Yang M, Eraksoy M et al NEUROLOGY 2007 68 12 Suppl 1 276-277
43. 835522 BG-12. Biogen Idec Inc COMPANY COMMUNICATION 2007 September 24